Literature DB >> 34787691

The risk factors for Graves' ophthalmopathy.

Jiamin Cao1, Yuhe Su2, Zhuokun Chen1, Chen Ma1, Wei Xiong3.   

Abstract

PURPOSE: This review aimed to provide an overview of current research into the risk factors for Graves' ophthalmopathy (GO).
METHODS: To find information about the risk factors for GO, the research database PubMed was searched and relevant articles were obtained to extract information about risk factors.
RESULTS: Smoking has been widely accepted as an important risk factor and cigarette smoking cessation has been shown to improve the outcome and decrease the onset of GO. Radioactive iodine on the thyroid may induce hyperthyroidism and increase the occurrence of GO. Selenium deficiency is a risk factor for GO and the supplementation of selenium has been an adjuvant therapy. Decreasing stressful life events (SLE) may help improve GO. Imbalance in intestinal flora is essential to GO, with Yersinia enterocolitica and Escherichia coli both increased in the digestive tract of the individual with GO. In addition, controlling serum cholesterol may help improve GO since adipogenesis is an important pathological change in its pathogenesis. Considering the correlation between Graves' disease and GO, maintaining normal thyroid function hormone level is the first-line therapeutic strategy to prevent progression of GO. An increase in antibodies such as TSHR and IGF-1R is the main predictor of GO. Besides, gender and gene polymorphism are also risk factors towards GO.
CONCLUSIONS: Risk factors for GO arise from five sources: physical and chemical environment, social-psychological environment, biological environment, the human organism, and genetic codes. Risk factors within these categories may interact with each other and their mechanisms in promoting the development of GO are complex. Research into risk factors for GO may promote emerging fields related to GO such as control of autoantibodies and intestinal microbiota.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Environment; Genetic codes; Graves’ ophthalmopathy; Human organism; Risk factor

Mesh:

Substances:

Year:  2021        PMID: 34787691     DOI: 10.1007/s00417-021-05456-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  79 in total

Review 1.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

Review 2.  Risk factors in periodontology: a conceptual framework.

Authors:  Philippe Bouchard; Maria Clotilde Carra; Adrien Boillot; Francis Mora; Hélène Rangé
Journal:  J Clin Periodontol       Date:  2016-12-16       Impact factor: 8.728

Review 3.  Differential involvement of orbital fat and extraocular muscles in graves' ophthalmopathy.

Authors:  Wilmar M Wiersinga; Noortje I Regensburg; Maarten P Mourits
Journal:  Eur Thyroid J       Date:  2013-02-26

Review 4.  IGF1 receptor and thyroid-associated ophthalmopathy.

Authors:  Michelle Mohyi; Terry J Smith
Journal:  J Mol Endocrinol       Date:  2017-12-22       Impact factor: 5.098

5.  Smoking induces overexpression of immediate early genes in active Graves' ophthalmopathy.

Authors:  Tereza Planck; Bushra Shahida; Hemang Parikh; Kristoffer Ström; Peter Åsman; Håkan Brorson; Bengt Hallengren; Mikael Lantz
Journal:  Thyroid       Date:  2014-09-19       Impact factor: 6.568

6.  Effect of smoking on orbital fat and muscle volume in Graves' orbitopathy.

Authors:  Noortje I Regensburg; Wilmar M Wiersinga; Tos T J M Berendschot; Peerooz Saeed; Maarten P Mourits
Journal:  Thyroid       Date:  2010-12-12       Impact factor: 6.568

7.  Hypoxia-Dependent HIF-1 Activation Impacts on Tissue Remodeling in Graves' Ophthalmopathy-Implications for Smoking.

Authors:  Gina-Eva Görtz; Mareike Horstmann; Barbara Aniol; Buena Delos Reyes; Joachim Fandrey; Anja Eckstein; Utta Berchner-Pfannschmidt
Journal:  J Clin Endocrinol Metab       Date:  2016-09-09       Impact factor: 5.958

8.  Proteomics of Orbital Tissue in Thyroid-Associated Orbitopathy.

Authors:  N Matheis; M Lantz; F H Grus; K A Ponto; D Wolters; H Brorson; T Planck; B Shahida; S Pitz; N Pfeiffer; G J Kahaly
Journal:  J Clin Endocrinol Metab       Date:  2015-10-09       Impact factor: 5.958

9.  Serial TSH-receptor antibody levels to guide the management of thyroid eye disease: the impact of smoking, immunosuppression, radio-iodine, and thyroidectomy.

Authors:  Jonathan C P Roos; Vignesh Paulpandian; Rachna Murthy
Journal:  Eye (Lond)       Date:  2018-11-06       Impact factor: 3.775

10.  The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.

Authors:  L Bartalena; G J Kahaly; L Baldeschi; C M Dayan; A Eckstein; C Marcocci; M Marinò; B Vaidya; W M Wiersinga
Journal:  Eur J Endocrinol       Date:  2021-08-27       Impact factor: 6.664

View more
  1 in total

1.  It takes two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.

Authors:  Leonard Girnita; Terry J Smith; Joseph A M J L Janssen
Journal:  J Clin Endocrinol Metab       Date:  2022-02-15       Impact factor: 6.134

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.